Francesco Lauria

Francesco Lauria

Ematologia E Trapianti, Università Di Siena - Aous, Siena, Italy, Siena, Italy,

Direct Impact

Concepts for which Francesco Lauria has direct influence:

idiopathic hypereosinophilic
eosinophilic leukemia
bone marrow
chronic myeloproliferative
peripheral blood
organ involvement
apparent aetiologies

External impact

Concepts related to the work of other authors for which Francesco Lauria has influence:

advisory committees
entitys board
moxetumomab pasudotox-tdfk
speakers bureau
leukemic cells
heavily pretreated
long-term follow-up

Prominent publications by Francesco Lauria

KOL-Index: 42 Standard treatment options in classic HCL (cHCL) result in high response rates and near normal life expectancy. However, the disease itself and the recommended standard treatment are associated with profound and prolonged immunosuppression, increasing susceptibility to infections and the risk for a severe course of COVID-19. The Hairy Cell Leukemia Foundation (HCLF) has recently convened ...
Known for
Leukemia Covid-19 | Management Chcl
KOL-Index: 38 OBJECTIVES: Infections are the major cause of morbidity and mortality in patients with acute myeloid leukaemia (AML). They primarily occur during the first course of induction chemotherapy and may increase the risk of leukaemia relapse, due to a significant delay in consolidation therapy. The intensification of induction chemotherapy and the use of non-conventional drugs such as fludarabine ...
Known for
Bacteremias | Induction Phase | Undetermined Origin | Leukaemia Relapse
KOL-Index: 33 Abstract Abstract 1371 Background: IGHV1-69 gene identifies the most frequent IGHV gene in chronic lymphocytic leukemia (CLL) and identifies the paradigm of unmutated CLL (U-CLL), being used in roughly 1/3 U-CLL. It is often rearranged to form subsets of stereotyped HCDR3 patterns, likely selected and transformed from the natural naïve B-cell repertoire ...
Known for
Ighv | Early Stage Cll | Indolent | Unmutated Status
KOL-Index: 33 One hundred and six patients aged
Known for
Fludarabine | 106 Aml | Mfi Mdr | P-Glycoprotein
KOL-Index: 27 Abstract Induction treatment of acute myeloid leukemia (AML) is conventionally based on regimens containing cytarabine (Ara-C), one anthracycline and, sometimes, a third drug, such as etoposide. Primary P-glycoprotein (Pgp) overexpression is the most important mechanism of multidrug resistance (MDR) in AML cells and it is almost always associated with less response to treatment. To ...
Known for
Ara | Induction Flai | Mdrve Cells | Pgp Expression
KOL-Index: 16 Minimal residual disease (MRD) following sequential administration of CHOP and rituximab was studied in previously untreated patients with follicular lymphoma. At diagnosis, the presence of Bcl-2/IgH-positive cells in the peripheral blood (PB) and/or bone marrow (BM) was demonstrated in all patients (n = 128) by polymerase chain reaction (PCR) analysis. Patients who achieved a clinical ...
Known for
Scheduled Mrd Follow-Up Program | Pcr Molecular | Seventy-Seven | Chop Achieved
KOL-Index: 14 Abstract Abstract 4029 Background: Azacitidine (AZA) at a dose of 75 mg/mq/day subcutaneously for 7 days, every 28 days, induces high hematologic response rates and prolongation of survival in high-risk MDS patients (pts) (Fenaux, 2009). However few data are hitherto available concerning the efficacy and safety of Aza in lower risk MDS. A lower dose ...
Known for
Lower Mds
KOL-Index: 11 We retrospectively analyzed the data of 337 patients with cytogenetically normal (CN) acute myeloid leukemia (AML), aged ≤ 65 years (training set). A prognostic index score (PIS) was calculated by totaling the score derived from the regression coefficients of each clinical variable, significantly associated with prognosis by multivariate analysis. The variables that were independent ...
Known for
Newest Biological Markers | Intermediate- Efs | Age ≥ | Prognostic Pis
KOL-Index: 10 In a phase II trial, we evaluated chlorambucil and rituximab (CLB-R) as first-line induction treatment with or without R as maintenance for elderly chronic lymphocytic leukemia (CLL) patients. Treatment consisted of eight 28-day cycles of CLB (8 mg/m(2) /day, days 1-7) and R (day 1 of cycle 3, 375 mg/m(2) ; cycles 4-8, 500 mg/m(2) ). Responders were randomized to 12 8-week doses of R (375 ...
Known for
First-Line Induction | 28-Day Cycles | Pfs Maintenance | Cd20 Gene Expression
KOL-Index: 9 Abstract BACKGROUND: The INTERIM study ( NCT 00858806) showed that in elderly (> 65 years) Ph+ CML patients selected for a stable complete cytogenetic response (CCgR) lasting > 2 years, the policy of intermittent imatinib treatment (one month on/one month off) may affect the markers of residual disease (CCgR and major molecular response, MMR or MR3.0), but ...
Known for
Consultancy Honoraria | Russo | Ariad | Ccgr Mmr

Ematologia e Trapianti, Università di Siena - AOUS, Siena, Italy, Siena, Italy,

© 2022 - Key Opinion Leaders -
Key Opinion Leaders, LLC ,
2025 NW 102 Avenue, Suite 111 Doral , FL   33172